Company Profile
Gain Therapeutics Stock Price, News & Analysis
- Ticker:
- GANX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
1.73 USD (-6.99%)
Close
Last updated: July 28, 2026
78.1M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, GANX closed down 6.99% at $1.73. No new same-company headline was identified in the current news window.
Company overview
Business overview
Gain Therapeutics is a biotechnology company focused on protein-modulation and neurological disease discovery. Its platform aims to use computational biology to create targeted therapeutics.
Geographic Base and Sector Classification
Headquartered in Switzerland and listed on NASDAQ, Gain has a global specialty-biotech profile.
Business Model Characteristics
The company depends on platform validation, translational data, and the ability to convert discovery science into value.
Position Within the Biotechnology Landscape
Gain is a platform biotech name whose valuation depends on early scientific and clinical progress.
Future catalysts
Gain’s catalysts are GPCR-focused neuroscience programs and any update that shows the company can still translate the biology into clinic. The market is waiting for a cleaner proof point.
Recent news
- 01
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Source: Gain Therapeutics
- 02
- 03
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Source: Gain Therapeutics
- 04
- 05
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Source: Gain Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gain Therapeutics (GANX)?
Gain Therapeutics (GANX) most recently closed at 1.73 USD, a -6.99% move versus the previous session.
What is the market cap of Gain Therapeutics (GANX)?
Gain Therapeutics currently has a market capitalization of 78.1M USD on BioPharmSignal.
What does Gain Therapeutics do?
Gain Therapeutics is a biotechnology company focused on protein-modulation and neurological disease discovery. Its platform aims to use computational biology to create targeted therapeutics.
On which exchange is GANX stock listed?
Gain Therapeutics (GANX) is associated with NASDAQ, Switzerland, Biopharma.
What is Gain?
Gain’s catalysts are GPCR-focused neuroscience programs and any update that shows the company can still translate the biology into clinic.
Which conditions is Gain Therapeutics targeting with Gain?
Gain Therapeutics is associated with neuroscience based on its company overview and current catalyst commentary.
How does Gain Therapeutics describe recent progress with Gain?
Gain’s catalysts are GPCR-focused neuroscience programs and any update that shows the company can still translate the biology into clinic.
What is Therapeutics?
Gain Therapeutics is a biotechnology company focused on protein-modulation and neurological disease discovery.